Research Paper Volume 13, Issue 3 pp 4503—4521

Identification of therapeutic targets and prognostic biomarkers from the hnRNP family in invasive breast carcinoma

HNRNPU expression is upregulated in BRCA cell lines and clinical tumor samples. Altering expression of HNRNPU proteins in clinical tumor samples (A) and four human BRCA cell lines (B), as determined via western blot analysis. Glyceraldehyde 3-phosphate dehydrogenase was used as the control. ZR-75-1 and MDA-MB-330 cells were transfected with shRNA and the mRNA (C), and protein (D) expression levels of HNRNPU were measured via reverse transcription quantitative real-time polymerase chain reaction and western blotting. *P P P

Figure 7. HNRNPU expression is upregulated in BRCA cell lines and clinical tumor samples. Altering expression of HNRNPU proteins in clinical tumor samples (A) and four human BRCA cell lines (B), as determined via western blot analysis. Glyceraldehyde 3-phosphate dehydrogenase was used as the control. ZR-75-1 and MDA-MB-330 cells were transfected with shRNA and the mRNA (C), and protein (D) expression levels of HNRNPU were measured via reverse transcription quantitative real-time polymerase chain reaction and western blotting. *P < 0.05; **P < 0.01; ***P < 0.001.